Introduction. The high frequency of recurrence of chronic bacterial prostatitis may be due to the weakening of local and systemic immunity. This determines the need for immunotropic therapy in this disease.
Target. To evaluate the effectiveness of «Tubosan» in the complex therapy of chronic bacterial prostatitis.
Materials and methods. A comparative controlled cohort study was conducted. The study included 60 men with a microbiologically confirmed diagnosis of chronic bacterial prostatitis. The main group received antibiotic therapy in combination with «Tubosan». Control - only antibiotic therapy. The duration of treatment in both groups was 28 days. All patients underwent an IPSS questionnaire, microscopy, and culture of prostate secretion.
Results and discussion. All patients of both groups showed complete eradication of pathogens according to the results of seeding of the secret of the prostate gland. In patients of the main group, a more pronounced decrease in symptoms was observed compared with the control. The sum of points on the IPSS scale before and after treatment in the main group was 21,9±1.3 vs 8.7±2.2, in the control group - 22.2±10.3 vs 10.3±1.4 points, respectively ( p<0.001). In the main group, there was a more significant decrease in the inflammatory process in the prostate. The average number of leukocytes in the field of view in the main group before and after treatment was 101.0±23.2 vs 5.2±1.3 cells (p<0.001), in the control group 101.6±21.5 vs 16.8±6.2 cells (p<0.001), respectively. After treatment, both groups showed a statistically significant improvement in the quality of life of patients, as assessed by the answer to question 7 of the IPSS questionnaire. In the main group, the average score on question No. 7 before and after treatment was 3.9±0.6 vs 1.8±0.5 points, respectively (p<0.001) 3.9±0.6 points vs 2.3±0.4 points, respectively (p<0.001).
Conclusion. «Tubosan» can be used as an immunotropic agent in the complex therapy of chronic bacterial prostatitis to improve treatment outcomes
